Big news from the lab of former Gabrielle’s Angels grantee Dr. Scott Armstrong and his colleagues at Dana Farber! A new drug that not only could treat acute myeloid leukemia but also potentially prevent the cancer from developing is now being evaluated in clinical trials.
This drug, SNDX-5613, successfully reversed leukemia development in mice and human cell lines and the drug’s efficacy will now be evaluated in patients as young as one month old.
Preclinical trial results show a dramatic reduction in leukemia cell counts, and, in some cases, cancer remission.
Congratulations to Dr. Armstrong and his team on these promising results!